← FDA Drug Approvals (Drugs@FDA)

NINTEDANIB ESYLATE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: BIOCON PHARMA · Approved 2026-08-19

Drug application

FDA Application #

ANDA220118

Application type

Abbreviated New Drug Application (Generic)

Brand name

NINTEDANIB ESYLATE

Generic name

Nintedanib Esylate

Active ingredients

NINTEDANIB ESYLATE

Dosage form

CAPSULE

Route

ORAL

Marketing status

Prescription

Sponsor

BIOCON PHARMA

First approval

2026-08-19

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown